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Introduction
Intra-abdominal infection (IAI) is an important cause of
morbidity and mortality. It is the second most com-
monly identified cause of severe sepsis in the intensive
care unit (ICU). Recent studies have associated severe
intra-abdominal infection with a significant mortality
rate.
Most IAI are a result of processes involving inflamma-
tion and perforations of the gastrointestinal tract, such
as appendicitis, peptic ulcer disease, and diverticulitis.
Patients with diffuse peritonitis may be due to sponta-
neous perforation, post-operative, post-interventional or
post-traumatic causes. The lower GI tract is most often
the location of perforation. Among patients with IAI
who develop peritonitis, many may progress to severe
sepsis, defined by The American College of Chest Physi-
cians/Society of Critical Care Medicine as a severe sys-
temic inflammatory response to infection that is
associated with acute organ dysfunction.
Successful treatment of IAI is based on early and
appropriate source recognition, containment and antimi-
crobial coverage. We will review clinical definitions,
pathophysiology, and treatment strategies for IAI in an
effort to provide guidelines for clinical management.
Definitions
Intra-abdominal infection (IAI) describes a diverse set
of diseases. It is broadly defined as peritoneal inflamma-
tion in response to microorganisms, resulting in puru-
lence in the peritoneal cavity [1]. IAI are classified as
uncomplicated or complicated based on the extent of
infection [2].
Uncomplicated abdominal infections involve intra-
mural inflammation of the gastrointestinal (GI) tract
without anatomic disruption. They are often simple to
treat; however, when treatment is delayed or inappropri-
ate, or the infection involves a more virulent nosocomial
microbe, the risk of progression into a complicated
abdominal infection becomes significant [3,4].
Complicated abdominal infections extend beyond
the source organ into the peritoneal space. They cause
peritoneal inflammation, and are associated with loca-
lized or diffuse peritonitis[5]. Localized peritonitis often
manifests as an abscess with tissue debris, bacteria, neu-
trophils, macrophages, and exudative fluid contained in
a fibrous capsule. Diffuse peritonitis is categorized as
primary, secondary or tertiary peritonitis.
Primary peritonitis is also known as spontaneous
bacterial peritonitis. It is thought to be the result of bac-
terial translocation across an intact gut wall [6]. These
infections are commonly monomicrobial, and the infect-
ing organism is primarily determined by patient demo-
graphics. For example, healthy young girls are most
often infected by streptococcal organisms, cirrhotics by
gram negative or enterococcal organisms, and peritoneal
dialysis patients by Staphylococcus aureus [7,8]. Diagno-
sis requires peritoneal fluid aspiration. Characteristics of
infection include white blood cell count (WBC) > 500
cells/mm
3, high lactate, and low glucose levels. Positive
peritoneal fluid cultures are definitive, and resolution of
infection is marked by peritoneal fluid with < 250
WBC/mm
3[9].
Secondary peritonitis is caused by microbial contam-
ination through a perforation, laceration, or necrotic
segment of the GI tract[7]. Definitive diagnosis is based
on clinical examination and history, and specific diag-
noses can be confirmed by radiographic imaging[10]. If
a patient is stable enough for transport, computed
tomography (CT) scan with intravenous and oral
contrast is the standard method of evaluating most
intra-abdominal pathologies, such as appendicitis, diver-
ticulitis, and colitis [11]. Suspected biliary pathology is
the exception, and ultrasound is the preferred initial
imaging modality for this spectrum of disease including
acute cholecystitis, emphysematous cholecystitis, and
cholangitis. Infections associated with secondary perito-
nitis are commonly polymicrobial and the infecting
organisms are those most commonly associated with the
source of contamination (see Table 1).
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persistent or recurrent at least 48 hours after appropri-
ate management of primary or secondary peritonitis. It
is more common among critically ill or immunocom-
promised patients [12]. Because of the poor host
defenses, it is also often associated with less virulent
organisms, such as Enterococcus, Candida, Staphylococ-
cus epidermidis, and Enterobacter[13].
Intra-abdominal sepsis is an IAI that results in
severe sepsis or septic shock[2].
Pathophysiology
The peritoneum divides the abdomen into the peritoneal
cavity and the retroperitoneum. The peritoneum is a
layer of mesothelium that lines the abdominal cavity. It
is abundantly innervated by the somatic nervous system.
This explains the intense localized pain that patients
experience when they have peritoneal inflammation or
injury. Functionally, it provides approximately one m
2 of
exchange area, and holds approximately 100 ml of peri-
toneal fluid, primarily consisting of macrophages and
lymphocytes[14,15]. Negative pressure generated by dia-
phragmatic relaxation causes peritoneal fluid to flow
upward toward a specialized system of diaphragmatic
fenestrae. This high flow system drains fluid into the
lymphatic system. During infection, this allows for rapid
efflux of micro-organisms and host defenses into the
venous system via the thoracic duct [16].
Perforation, and the bacterial innoculation that ensues,
causes an inflammatory response that acts locally to con-
tain the infection; but, in the setting of overwhelming con-
tamination, it can spread to cause systemic inflammation.
Several mechanisms act locally to contain or destroy
infection. Tissue injury stimulates mast cell degranula-
tion. Mast cell degranulation releases histamine, kinins,
leukotrienes, prostacyclines, and free radicals. These fac-
tors increase vascular and peritoneal permeability
allowing for local influx of complement and coagulation
cascade factors.
Influx of complement at the site of contamination
allows for bacterial opsonization via C3b. Diaphragmatic
motion, described above, then leads to absorption of
bacteria laden peritoneal fluid into the lymphatic system.
Opsonised organisms in the lymph are transported to
the reticuloendothelial system, where they are destroyed.
In addition to bacterial destruction via opsonization,
complement also attracts neutrophils to the site of
injury via chemotactic factors C3a and C5a. Neutrophils
attack bacteria by three mechanisms: first they express
and release more cytokines further propagating the
inflammatory response; second, they phagocytose and
destroy bacteria via respiratory burst; third they secrete
neutrophil extracellular traps (NETs). NETs are com-
p o s e do fD N A ,c h r o m a t i na n ds e r i n ep r o t e a s e s .N E T s
can both destroy extracellular organisms without phago-
cytosis, and act as a physical barrier to prevent the
further spread of pathogens [17]. Finally, tissue factor,
expressed by injured tissue, leads to activation of the
coagulation cascade. This results in increased fibrin pro-
duction, necessary to contain bacteria by abscess
formation.
These cellular processes can also have systemic effects,
as the products of mast cell degranulation at the site of
injury move into the circulatory system. There, in addi-
tion to increased vascular permeability, they cause
smooth muscle relaxation and can result in peripheral
vascular collapse. Free radicals released with degranula-
tion cause lipid peroxidation of cell membranes result-
ing in further release of toxic granulation products.
Granulocytes and macrophages, attracted to the site of
injury by the complement chemotactic factors C3a and
C5a, release acute phase cytokines such as IL-1, IL-6,
TNF-a,I F N - g. These cytokines are released into the
peripheral circulation where they cause fever, cortisol
release, acute phase protein synthesis, leukocytosis, and
lymphocyte differentiation and activation. The resultant
physiologic state is clinically known as the Systemic
Inflammatory Response Syndrome (SIRS). SIRS is
defined by the presence of at least two of the following:
core body temperature > 38°C or < 36°C, heart rate >
90 beats per minute, respiratory rate > 20 breaths per
minute (not ventilated) or PaCO2 < 32 mmHg (venti-
lated), WBC > 12,000, < 4,000, or > 10% immature
forms (bands)[18]. When SIRS is associated with a bac-
terial source, as with cases of IAI, it is known as sepsis.
When sepsis is paired with organ failure, it is known as
severe sepsis.
Management
Management of IAI requires resuscitation, source con-
trol, and antibacterial treatment. The most important of
Table 1 Expected organisms according to source
Source Expected Organism
Primary
Peritonitis
Young healthy
female
Streptococcus
Cirrhotic Enteric gram negatives Enterococcus
CAPD Staphylococcus aureus
Secondary
peritonitis
Stomach and
duodenum
Streptococcus Lactobacillus
Biliary E. coli, Klebsiella, Enterococcus
Small Intestine E. coli, Klebsiella, Lactobacillus
Streptococci Diptheroids Enterococci
Distal ileum
and colon
Bacteroides fragilis Clostridium spp. E.
coli Enterobacter spp. Klebsiella spp.
Peptostreptococci Enterococci
Teritiary
peritonitis
Enterococcus Candida Staphylococcus
epidermidis Enterobacter
Adapted from Weigelt JA [12].
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measures undertaken to eliminate the source of infec-
tion and to control ongoing contamination”[19]. There
are three key components of source control: drainage,
debridement, and definitive management.
Resuscitation and Support of Organ Systems
IAI causes volume depletion by several mechanisms.
Nausea, anorexia and ileus lead to a decrease in oral
intake, while vomiting and diarrhea increase sensible
losses. In addition, ileus with third space losses into the
bowel wall and ascites, as well as fever both increase
insensible losses. Elevated body temperature leads to
both an increase in dermal loss via sweating, and an
increase in respiratory loss by causing tachypnea. Dermal
loss in a febrile patient can account for approximately
600 ml of volume loss per day, while tachypnea causes
approximately 100 ml of volume loss per day [20,21].
In uncomplicated IAI, replacing volume is essential; in
severe sepsis or septic shock, it becomes critical.
Patients suspected of having severe sepsis or septic
shock should be admitted to an ICU for careful moni-
toring of vital signs and volume status. With regard to
the initial volume resuscitation, we recommend follow-
ing the Surviving Sepsis Campaign recommendations.
As soon as hypotension is recognized, or, ideally if it is
anticipated, attention should be paid to early goal direc-
ted volume resuscitation. Isotonic fluid, or in the cases
of severe anemia or coagulopathy, blood products,
should be administered with the intent to achieve a
mean arterial pressure (MAP) > 65 mmHg and a central
venous pressure (CVP) of 12-15 mmHg within the first
6 hours [22]. If a MAP > 65 mmHg cannot be obtained
by volume resuscitation alone then vasopressors should
be used, with a preference for norepinepherine or dopa-
mine [22]. In cases where low cardiac output or elevated
filling pressures indicate severe myocardial dysfunction,
use of inotropic agents such as dobutamine may be effi-
cacious in obtaining adequate MAP [22]. Care should
also be taken to monitor clinical indicators of end organ
perfusion, such as hourly urine output and mental sta-
tus, to ensure adequate oxygen delivery.
The goal of resuscitation is correction of cellular oxy-
gen debt. Various endpoints for resuscitation have been
suggested, including: mixed venous oxygen (SVO2), lac-
tate and base deficit. While a normal or high SVO2 does
n o te n s u r ea d e q u a t et i s s u eo x y g e n a t i o n ,al o wS V O 2
indicates a need to increase tissue oxygenation. Resusci-
tation to maintain an SVO2 > 65% has been shown to
improve outcomes [23,24]. Lactate, a product of anaero-
bic metabolism, has also been used as an indirect mea-
sure of oxygen debt. More recently sepsis has been
recognized as a hypermetabolic state that uses glycolysis
in the absence of hypoxia, making it less reliable as a
marker of oxygen debt. Still, its early normalization may
predict improved outcomes [25-27]. Base deficit is yet
another indicator of oxygen debt. It describes the amount
of base that would be required to bring the blood to a
normal pH under normal physiologic conditions. The
degree of base deficit has been shown to correlate with
resuscitation requirements and mortality [28,29]. While
none of these measures are perfect, they can be helpful in
guiding resuscitation when used in combination with the
other clinical endpoints discussed above.
Drainage
The goal of drainage is to evacuate purulent, contami-
nated fluid, or to control drainage of ongoing enteric
contamination. This is accomplished by either percuta-
neous or open surgical intervention. Percutaneous drai-
nage can be performed with or without image guidance,
and is most commonly performed using ultrasound or
CT. In many circumstances it is as efficacious as surgi-
cal drainage, and is often used as the initial treatment of
choice because it is less invasive and more affordable
[30,31]. Percutaneous drainage is also useful in patients
who are poor surgical candidates, and might not survive
definitive surgical treatment. However, percutaneous
drainage is unlikely to result in adequate source control
in cases of frank bowel perforation with ongoing con-
tamination, or if there is a significant amount of necro-
tic tissue present. In these cases, surgery is the
treatment of choice.
Open surgical drainage should be used in the case of
generalized peritonitis, ongoing gross contamination
from an uncontrolled enteric source, if bowel necrosis
or ischemia is suspected, and in cases of failure of per-
cutaneous drainage. Unstable patients, or those with
complicated or difficult anatomy such as post-operative
patients or those with advanced malignancy pose a par-
ticular challenge.
In these situations, damage control techniques can be
employed with temporary abdominal closure. Damage
control procedures are typically used for patients who
are unstable and unable to tolerate definitive surgical
treatment, have intra-abdominal hypertension (IAH), or
have loss of abdominal domain that prevents fascial clo-
sure. The first stage in damage control surgery is eva-
cuation of infected material and control of gross
contamination. This is followed by temporary abdominal
closure with a conventional dressing, negative pressure
dressing, or skin closure. This first operative stage is fol-
lowed by ongoing resuscitation, once normal physiology
is restored resuscitation can then be followed by
planned re-laparotomy for definitive source control and
reconstruction. In cases of physiologic worsening after
first laparotomy, or in cases of concern for IAH, or
intestinal ischemia, on demand repeat laparotomy can
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addressed, physiology has been restored and there are
no longer concerns for ongoing ischemia, necrosis, or
IAH the abdomen can be definitively closed.
Intra-abdominal lavage is a subject of ongoing contro-
versy. Proponents of peritoneal lavage reason that con-
tamination is both removed and diluted by lavage
volumes greater than 10 L, additionally, by adding anti-
biotics bacterial pathogens can be specifically targeted.
One group has suggested that lavage with volumes of
approximately 20 L reduces infectious complications in
blunt traumatic small bowel perforation [32]. However,
its application with or without antibiotics in abdominal
sepsis is largely unsubstantiated; at this time there is
minimal evidence in the literature to support its use
[33,34].
Debridement
Debridement is essential for removal of foreign bodies,
fecal matter, hematoma, and infected or necrotic tissue.
The necessity to remove fibrin deposits is controversial.
One early study showed improved postoperative courses
with fewer continued infections; however, more recent
studies have shown no benefit to this strategy [35,36].
Definitive management
Definitive management involves restoration of anatomy
and function. While staged procedures were once the
standard, single stage procedures with primary anasto-
moses have become accepted as both safe and cost
effective in the stable patient[ 3 7 ] .S t i l l ,e s t a b l i s h i n g
bowel continuity may need to be delayed in patients
who are unable to tolerate a lengthy procedure or have
inadequate capacity for tissue healing [38].
Specific Surgical Pathologies
Appendicitis
Acute appendicitis is the most common intra-abdominal
surgical emergency [19]. Lifetime risk is approximately
7-9% [39]. Currently, imaging is recommended for all
patients suspected of having appendicitis except men
under 40 years of age [40]. Generally, CT scan is the
accepted imaging modality,h o w e v e r ,u l t r a s o u n dm a y
have a role in women at risk for other pelvic patholo-
gies, in pregnancy and in children [41]. The sensitivity
and specificity of CT scan in the diagnosis of acute
appendicitis are 87-100% and 91-98%, respectively
[42,43]. Ultrasound is very user dependent, and results
can be affected by patient body habitus, however overall
sensitivity is 76-96% and specificity is 91-100% [44].
Ultrasound, with its decreased cost, lack of ionizing
radiation and ability to assess ovarian pathology, has
been the preferred initial imaging modality in children
[45-47]. However, CT should be used in children when
the initial ultrasound is negative or non-diagnostic and
there is a high clinical suspicion for appendicitis [45,48].
Ultrasound is also the initial imaging procedure of
choice in pregnant women, however, the appendix is
visualized only 13-50% of the time. Magnetic resonance
imaging (MRI) is an emerging imaging modality for
cases of appendicitis in pregnancy with non-visualization
of the appendix on ultrasound. Its sensitivity and specifi-
city are 100% and 93.6%, respectively [49].
Though acute appendicitis is a very common entity, its
management still contains areas of controversy including
the role of laparoscopy, and the emerging role of medi-
cal management. These decisions can be complicated by
the presence of an abscess or phlegmon.
Surgical management of acute appendicitis has been
the gold standard of treatment for decades. However,
many groups have proposed that in select patients,
acute uncomplicated appendicitis can be treated with
antibiotics alone. Initial success rates for conservative
management of acute appendicitis range from 88-95%;
however, recurrence is common, occurring in up to 35%
of cases [50].
Both laparoscopic and open appendectomy are safe
and effective. In large reviews, laparoscopic appendect-
omy has been associated with fewer surgical site infec-
tions, less pain, shorter hospital stays, and more rapid
return to normal activity [51]. Common disadvantages
found include increased cost and longer operative times
[52,53]. Additionally, laparoscopy has been associated
with increased risk of intra-abdominal abscess forma-
tion, especially in the presence of perforation or gang-
rene. In these cases, open surgery may be preferred [54].
Ultimately, the differences in outcomes between laparo-
scopic and open appendectomy are largely equivocal
and the decision should be based on available technol-
ogy and surgeon expertise, with increased consideration
for laparoscopy in young female or obese patients
[51,55,56].
Management of patients presenting with abscess or
phlegmon is conservative, with antibiotics and drainage
initially. Traditionally this has been followed by interval
appendectomy. However, recently the need for interval
appendectomy has been questioned. Controversy pri-
marily surrounds the issues of recurrence and potential
for malignancy. In a large review the recurrence rate
was 7.4% and the risk of malignancy 1.2% [57]. This is
in accord with similar studies that conclude that in
asymptomatic patients, interval appendectomy has no
advantages over a thorough work up for inflammatory
appendiceal masses [58,59].
Gastroduodenal perforation
After bleeding, perforation is the second most common
complication requiring emergent operative intervention
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tion is the most common cause of gastric and duodenal
ulcers. Since the development of treatments for
H. pylori, its prevalence in the United States has
decreased. However, prevalence of gastric and duodenal
ulcers has remained the same [62].
Previously, ulcer perforation was treated by excision
and vagotomy. However, with antimicrobial eradication
and anti-secretory pharmaceuticals, H. pylori positive
ulcer recurrence has been significantly reduced [63]. As a
result, the current standard of care is simple ulcer exci-
sion and primary repair of the bowel defect, or omental
patch and subsequent H. pylori eradication, with little or
no role for anti-secretory ulcer surgery [61,64].
Both open and laparoscopic approaches are reasonable
options for treatment of perforated peptic ulcers.
Laparoscopic surgery is associated with significantly less
pain, but downfalls include longer operative times, and
potentially inadequate repair of large perforations. Com-
parisons of sutured versus non-sutured repair with fibrin
glue plug reveal that both are safe [65].
Conservative management has also been proposed as a
safe option for management of contained or sealed gas-
troduodenal perforations. One randomized study
showed similar morbidity and mortality for operative
and conservative approaches; however, conservative
treatment was associated with longer hospital stays and
increased failure in patients over 70 years old [66]. Simi-
larly, another author suggests that patients less than
40 years old and not on NSAIDS are the most likely to
be infected with H. pylori and therefore, the most likely
to benefit from non-operative therapy [67]. Alterna-
tively, one group suggests that non-operative therapy
can be guided by documented self-sealing on gastroduo-
denogram [68].
Diverticulitis
Diverticular disease has increased since the turn of the
20th century [69]. The prevalence of diverticular disease
among the general population is unknown, but at
autopsy more than 50% of people over 80 years old are
affected [70]. The lifetime prevalence of diverticulitis
among patients with diverticulosis is 10-25% [69].
The standard treatment for uncomplicated diverticuli-
tis is bowel rest and antibiotics. Most patients with
uncomplicated diverticulitis respond to conservative
management. Two studies found that patients who did
not respond to antibiotics within 48 hours were more
likely to require prolonged hospital stays for IV antibio-
tics and/or surgical intervention [71,72].
Diverticulitis can be complicated by phlegmon, abscess,
or free perforation and is generally classified according to
modified Hinchey criteria [73]. Approximately 15-20% of
cases are associated with abscesses [74]. In cases of
uniloculated abscess, the initial treatment is usually per-
cutaneous drainage; although, in small abscesses (< 4
cm), antibiotics have been used as a primary treatment
with success rates comparable to drainage [75,76]. When
percutaneous drainage is performed it has success rates
of up to 90% [77]. Of importance, the success of percuta-
neous drainage also seems to be dependent upon loca-
tion. Ambrosetti and colleagues found that compared to
mesocolic abscesses, pelvic abscesses were more aggres-
sive, needed earlier drainage, and were more likely to
require surgery [78].
Traditionally, patients who present with an abscess or
phlegmon then undergo elective surgery to avoid the high
risk of recurrence and further complications [71,73].
Recently though, some have begun to question the need for
operative therapy when initial management with percuta-
neous drainage and antibiotics is successful [79]. Two
authors have found that perforation, which is the most
common cause of mortality in complicated diverticulitis, is
more likely to be the initial presentation of disease, rather
than a manifestation of recurrence [79,80]. They concluded
that abscesses in complicated diverticulitis might then be
adequately managed with antibiotics and drainage alone.
While conservative management may be appropriate in
uniloculated abscesses, timely initial operative manage-
ment is required for cases in which abscesses are large,
multiloculated, or inaccessible, as well as in cases of free
perforation, or diffuse peritonitis. Acute diverticulitis is
complicated by free perforation in approximately 1.5% of
episodes [81]. The standard procedure in cases of peritoni-
tis is a Hartmann’s procedure. However, the Hartmann’s
procedure is associated with significant morbidity and
mortality, and while it can ber e v e r s e di n3 - 6m o n t h s ,
30-70% of patients never undergo reversal [82-86].
Recently, it has been suggested that primary resection and
anastomosis should be preferred [83,86,87]. Finally, laparo-
scopic resections for complicated diverticulitis have also
been shown to be safe; and, in spite of longer operative
times, they are associated with fewer major complications,
less pain, and shorter hospital stays [88].
Antibiotic Therapy
Surgery is the definitive treatment for complicated IAI,
but systemic antibiotic therapy is a necessary adjunct.
The role of antibiotics in this setting is prevention and
treatment of hematogenous spread of infection and
reduction of late complications [89]. Treatment should
be initiated as soon as a diagnosis is suspected, and
within an hour in the case of severe sepsis [22]. Antibio-
t i cc h o i c es h o u l dd e p e n do nt h em o s tl i k e l ys o u r c eo f
infection, immune status of the patient, and the likeli-
hood of opportunistic or resistant organisms.
In general, the gastrointestinal tract is sterile in the
stomach and duodenum, with enteric gram negatives in
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distal ileum and colon [7]. Table 1 lists the expected
organisms according to source of contamination.
In cases where the source is known, antimicrobial
selection can target site-specific organisms. When the
source is not known, choice of antimicrobial regimen
and duration of treatment should be guided by patient
risk. Risk, in this context, is intended to describe risk
for failure of treatment, and risk assessment allows for
proper selection of narrow versus broad-spectrum anti-
biotics. High versus low risk is determined primarily by
patient physiology and underlying medical conditions
(Table 2). Health care-associated infections, APACHE II
score > 15, advanced age, organ dysfunction, poor nutri-
tional status, immunosuppression and presence of
malignancy are all associated with a high risk of treat-
ment failure [5,12].
Without identifiable risk factors, an IAI is considered
low risk and can be treated with narrow-spectrum anti-
biotics directed toward anaerobic and gram-negative
organisms [7]. In low risk infections, cultures are gener-
ally considered unnecessary. Even if cultures are
obtained and show resistant organisms, there is no need
to alter antimicrobial therapy according to culture
results if there is an adequate clinical response [5].
Table 3 lists antibiotic regimens deemed appropriate for
low risk patients by the Surgical Infection Society (SIS).
High-risk patients require the use of broad-spectrum
antibiotics with anticipation of resistant organisms (see
Table 3). Additionally, in high-risk patients attention
should be given to the antibiograms of the particular
institution, with initial antibiotic choice tailored to the
risk of methicillin or vancomycin resistant organisms,
and extended spectrum beta lactamase producers. Com-
pared to patients initially treated with broad-spectrum
antibiotics, patients who receive inadequate empiric
treatment have longer hospital stays, higher rates of
postoperative abscesses and re-operation, and increased
mortality [90,91]. Furthermore, changing regimens in
response to cultures that display resistance does not
improve outcomes [90]. Therefore, the use of broader-
spectrum agents from the outset appears crucial to opti-
mizing outcomes in high-risk patients. While cultures
do not alter outcomes in high risk patients, it is
recommended that cultures be obtained in this group in
order to de-escalate antibiotic therapy to avoid increas-
ing resistance [40].
Infections that Require Special Consideration
MRSA
Though an uncommon cause of IAI, MRSA deserves
special consideration. Treatment often includes vanco-
mycin, which has a low bactericidal activity and achiev-
able tissue concentrations of the drug may not meet the
minimum inhibitory concentration (MIC) [92]. As a
result, these infections may require longer courses of
antimicrobial therapy [89]. Continuous infusion of van-
comycin may be a solution to this problem. In addition,
newer antibacterials such as linezolid, tigecycline, erta-
penem, and moxifloxacin are also promising, and have
demonstrated non-inferiority in several studies of IAI
[40,92-95].
Enterococcus
The use of antibiotic therapy for Enterococcus in IAI is
controversial. Enterococcus can often be isolated from
IAI, and is associated with increased risk of treatment
failure and higher mortality [96,97]. However, outcomes
in these patients have shown to be independent of anti-
biotic coverage for enterococcus [97,98]. Currently, the
general consensus regarding enterococcal coverage is
that community-acquired infections require no coverage,
however ampicillin, or vancomycin should be added to
cover the following high risk patient groups: 1) patients in
septic shock who have received prolonged treatment with
cephalosporins or other antibiotics that select for Entero-
coccus, 2) immunocompromised patients, 3) patients with
prosthetic heart valves, or other intravascular prosthetic
devices, or 4) patients with health care associated/recur-
rent intra-abdominal infection [40,99]. Finally, vancomycin
resistant enterococcal (VRE) infections occur in patients
who are immunocompromised, previously colonized with
Table 2 Risk factors for poor outcomes
Factors associated with high risk for poor outcomes
Pre-existing factors Disease specific
Poor nutritional status APACHE II score ≥ 15
Presence of malignancy Delay in initial intervention > 24 hours
Organ dysfunction Inadequate source control
Immunosuppression Prolonged pre-operative hospital stay
Prolonged pre-operative antibiotics
Adapted from Weigelt JA, Solomkin, Wacha [4,12,40,109].
Table 3 Risk stratified antibiotic recommendations
Low Risk High Risk
Single Agent Cefoxitin Imipenem-cilastatin
Ertapenem Meropenem
Moxifloxacin Doripenem
Ticarcillin Pipercillin-tazobactam
Tigecycline
Combination Cefazolin Cefepime
Cefuroxime Ceftazidime
Ceftriaxone Ciprofloxacin
Cefotaxime Levofloxacin
Ciprofloxacin +Metronidazole
Levofloxacin
+Metronidazole
Adapted from Solomkin[4,5] (Infectious Diseases Society of America
Guidelines).
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stances VRE should be suspected and treated with alterna-
tives such as linezolid, tigecycline, or daptomycin. In the
absence of these risk factors, specific coverage for VRE is
not recommended [40].
Candida
Candida is similar to Enterococcus, in that isolation of
Candida from intra-abdominal cultures is associated
with increased mortality, but anti-fungal treatment has
not been shown to alter this risk [101]. Therefore, fungal
coverage is unnecessary unless the patient is immuno-
compromised, has a severe IAI with Candida grown
from intra-abdominal cultures, or has perforation of a
gastric ulcer while on acid suppressive medications [102].
Fluconazole is an appropriate initial choice for Candida
albicans peritonitis. However, increasingly, non-albicans
Candida spp., with resistance to commonly used anti-
fungals are responsible for candidemia [103,104]. Studies
have shown that echinocandins are both safe and effec-
tive in the treatment of invasive candidiasis. Therefore, in
critically ill patients echinocandins, such as caspofungin
or echinofungin, should be considered for primary treat-
ment [102,104]. Required treatment duration for Can-
dida peritonitis is 2-3 weeks [102].
Duration of Treatment
Because resistant organisms have been linked to impru-
dent use of antibiotics, it is important to limit the dura-
tion of antimicrobial treatment [105]. Previously, studies
have suggested limiting treatment duration for IAI by
discontinuing antibiotics when fever and leukocytosis
have resolved, and the patient is tolerating an oral diet
[106]. More recently, it has been suggested that fixed
duration treatment has similar efficacy [107]. The Surgi-
cal Infection Society (SIS) recommends that duration for
complicated abdominal infections should be limited to
4-7 days, and may be discontinued sooner in the absence
of clinical signs of infection [40]. In addition, once patients
are able to tolerate oral intake, antibiotic therapy can be
transitioned to oral dosing for the remainder of their treat-
ment without increased risk of failure [108]. Suggested
oral regimens for patients in whom resistance is not a con-
cern are listed in Table 4. Of note, lack of resolution of
clinical signs of infection after 7 days of antibiotics implies
failed source control, tertiary peritonitis, or new infection.
Further diagnostic work up including labs, cultures and
imaging to look for new or continued sources of infection
is essential, and should be accompanied by further surgical
intervention if warranted [2].
Finally, we must consider patients with acute IAI, for
which prompt source control is achieved. In cases where
adequate source control is accomplished within
12-24 hours, less than 24 hours of antibiotic treatment
is necessary (Table 5). Antibiotic choice in these
instances should generally be guided by the aforemen-
tioned recommendations for low risk infections.
Conclusion
Successful management of IAI is multi-factorial. Source
control is of primary importance. Prompt and judicious
antibiotic therapy is also necessary. Appropriate antibio-
tic therapy requires patient risk stratification. Duration
of antibiotic treatment should be limited to one week,
followed by re-evaluation and intervention as needed.
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